CardiacSense is a privately-owned startup that develops state of the art Bio-Sensing technology since 2009. CardiacSense has developed the world first clinically proven medical wearable device for monitoring heart arrhythmias. The CardiacSense watch combines PPG technology for 24/7 continuous monitoring and ECG for instantaneous Electro Cardiogram readings. The company is focused on Atrial Fibrillation and Cardiac Arrest and plan to have FDA clearance by the end of 2021. The company has won a contract from a tier-1 wristwatch manufacturer to develop an algorithm for continuous wrist-based Blood Pressure and plans to have FDA clearance for blood pressure towards the end of 2021. CardiacSense technology is based on a strong IP portfolio spread over the fields of optics, mechanics and signal processing. The company plans to expand its activities soon to continuous monitoring of heart failure.